IBM's innovative analogue computer chip, designed for AI, offers enhanced energy efficiency and may address the tech sector's growing environmental concerns.
IBM's analogue chip can run an AI speech recognition model 14 times more efficiently than traditional chips due to its compute-in-memory design.
The AI industry's energy demands have surged, with AI's carbon footprint nearing that of some developed nations; this chip could be a solution to these rising concerns.A new breakthrough in tech may have just solved artificial intelligence’s energy problems. AI requires a massive and growing amount of energy, and is producing more and more greenhouse gas emissions as the sector continues to expand.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
British chip-maker Arm snubs London and aims for New York stock exchange listingBRITISH chip-maker Arm fired the starting gun on plans for a New York stock exchange listing after snubbing London. The Cambridge-based firm is expected to fetch a valuation of around £50billion, m…
Lire la suite »
Qualcomm's new gaming handheld chip has Steam Deck and AMD in its sightsMuch more than merely a souped up phone chip.
Lire la suite »
IBM sells off The Weather Company to Francisco PartnersWhat better time for private equity to capitalize on changing climate
Lire la suite »
IBM shows off its sense of humor in not-so-funny letter leakInternal memos detail discontinued Dad-joke products
Lire la suite »
Adding immunity to human kidney-on-a-chip advances cancer drug testingA growing repertoire of cell and molecule-based immunotherapies is offering patients with indomitable cancers new hope by mobilizing their immune systems against tumor cells. An emerging class of such immunotherapeutics, known as T cell bispecific antibodies (TCBs), are of growing importance with several TCBs that the U.S. Food and Drug Administration (FDA) approved for the treatment of leukemias, lymphomas, and myelomas.
Lire la suite »